16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome

Lupus ◽  
2021 ◽  
pp. 096120332110203
Author(s):  
Savino Sciascia ◽  
Massimo Radin ◽  
Irene Cecchi ◽  
Roger A Levy ◽  
Doruk Erkan
Keyword(s):  
Risk Stratification ◽  
Antiphospholipid Syndrome ◽  
Antiphospholipid Antibodies ◽  
Task Force ◽  
Current Knowledge ◽  
Clinical Manifestations ◽  
International Congress ◽  
Level Of Evidence ◽  
Task Force Report

The objectives of the 16th International Congress on Antiphospholipid Antibodies (aPL) Task Force on Clinical Manifestations of Antiphospholipid Syndrome (APS) were to critically analyze: a) the definition of “APS”; b) the current knowledge on non-traditional manifestations associated with aPL; and c) the risk stratification strategies in aPL-positive patients. The quality of evidence was assessed by the GRADE system. The task force concluded that: a) APS does not have a uniform definition given the heterogeneity of the clinical presentations and different aPL profiles; b) current literature supports the role for aPL testing in cases of thrombocytopenia and recurrent cardiac events but are limited by vast heterogeneity, providing an overall low-to-very low level of evidence; and c) risk stratification strategies in aPL-positive patients, such as aPL-Score and Global APS Score, can be useful in clinical practice. International multicenter studies are still highly needed to improve the quality of available evidence and consequently the strength of future recommendations.

scholarly journals 14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends

2014 ◽  
Vol 13 (6) ◽  
pp. 685-696 ◽  
Author(s):  
Doruk Erkan ◽  
Cassyanne L. Aguiar ◽  
Danieli Andrade ◽  
Hannah Cohen ◽  
Maria J. Cuadrado ◽  
...  
Keyword(s):  
Antiphospholipid Syndrome ◽  
Antiphospholipid Antibodies ◽  
Task Force ◽  
International Congress ◽  
Task Force Report ◽  
Treatment Trends

14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends

2014 ◽  
Vol 13 (9) ◽  
pp. 917-930 ◽  
Author(s):  
Maria Laura Bertolaccini ◽  
Olga Amengual ◽  
Laura Andreoli ◽  
Tatsuya Atsumi ◽  
Cecilia B. Chighizola ◽  
...  
Keyword(s):  
Antiphospholipid Syndrome ◽  
Antiphospholipid Antibodies ◽  
Task Force ◽  
International Congress ◽  
Laboratory Diagnostics ◽  
Task Force Report

16th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome

Lupus ◽  
2020 ◽  
Vol 29 (12) ◽  
pp. 1594-1600
Author(s):  
Ricard Cervera ◽  
Ignasi Rodríguez-Pintó ◽  
Kim Legault ◽  
Doruk Erkan
Keyword(s):  
Antiphospholipid Syndrome ◽  
Antiphospholipid Antibodies ◽  
Task Force ◽  
International Congress ◽  
Precipitating Factors ◽  
Catastrophic Antiphospholipid Syndrome ◽  
Task Force Report ◽  
Laboratory Features ◽  
Diagnosis And Classification

The Task Force on Catastrophic Antiphospholipid Syndrome (CAPS) met again on occasion of the 16th International Congress on Antiphospholipid Antibodies (aPL) that was held in Manchester, England, in September 2019. Its aims were to assess the up-to-date knowledge on pathogenesis, clinical and laboratory features, diagnosis and classification, precipitating factors, and treatment of CAPS. This article summarizes the main aspects that were presented during the Task Force meeting at that Congress.

14th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome

2014 ◽  
Vol 13 (8) ◽  
pp. 795-813 ◽  
Author(s):  
Guilherme R. de Jesus ◽  
Nancy Agmon-Levin ◽  
Carlos A. Andrade ◽  
Laura Andreoli ◽  
Cecilia B. Chighizola ◽  
...  
Keyword(s):  
Antiphospholipid Syndrome ◽  
Antiphospholipid Antibodies ◽  
Task Force ◽  
International Congress ◽  
Task Force Report ◽  
Obstetric Antiphospholipid Syndrome

14th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome

2014 ◽  
Vol 13 (7) ◽  
pp. 699-707 ◽  
Author(s):  
Ricard Cervera ◽  
Ignasi Rodríguez-Pintó ◽  
Serena Colafrancesco ◽  
Fabrizio Conti ◽  
Guido Valesini ◽  
...  
Keyword(s):  
Antiphospholipid Syndrome ◽  
Antiphospholipid Antibodies ◽  
Task Force ◽  
International Congress ◽  
Catastrophic Antiphospholipid Syndrome ◽  
Task Force Report

16th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome

Lupus ◽  
2020 ◽  
Vol 29 (12) ◽  
pp. 1601-1615 ◽  
Author(s):  
Guilherme R de Jesús ◽  
Ashley E Benson ◽  
Cecilia B Chighizola ◽  
Savino Sciascia ◽  
David W Branch
Keyword(s):  
Antiphospholipid Syndrome ◽  
Antiphospholipid Antibodies ◽  
Task Force ◽  
International Congress ◽  
Clinical Aspects ◽  
Task Force Report ◽  
Obstetric Morbidity ◽  
Obstetric Antiphospholipid Syndrome ◽  
Obstetric Aps ◽  
Based Medicine

Obstetric antiphospholipid syndrome (APS) remains a clinical challenge for practitioners, with several controversial points that have not been answered so far. This Obstetric APS Task Force met on the 16th International Congress on Antiphospholipid Antibodies in Manchester, England, to discuss about treatment, diagnostic and clinical aspects of the disease. This report will address evidence-based medicine related to obstetric APS, including limitations on our current management, the relationship between antibodies against domain 1 of β2GPI and obstetric morbidity, hydroxychloroquine use in patients with obstetric APS and factors associated with thrombosis after obstetric APS. Finally, future directions for better understanding this complex condition are also reported by the Task Force coordinators.

scholarly journals 16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends

Lupus ◽  
2020 ◽  
Vol 29 (12) ◽  
pp. 1571-1593
Author(s):  
Hannah Cohen ◽  
Maria J Cuadrado ◽  
Doruk Erkan ◽  
Ali Duarte-Garcia ◽  
David A Isenberg ◽  
...  
Keyword(s):  
Antiphospholipid Syndrome ◽  
Antiphospholipid Antibodies ◽  
Task Force ◽  
Activity Index ◽  
Oral Anticoagulants ◽  
Damage Index ◽  
International Congress ◽  
Current Status ◽  
Task Force Report ◽  
Treatment Trends

Antiphospholipid syndrome (APS), an acquired autoimmune thrombophilia, is characterised by thrombosis and/or pregnancy morbidity in association with persistent antiphospholipid antibodies. The 16th International Congress on Antiphospholipid Antibodies Task Force on APS Treatment Trends reviewed the current status with regard to existing and novel treatment trends for APS, which is the focus of this Task Force report. The report addresses current treatments and developments since the last report, on the use of direct oral anticoagulants in patients with APS, antiplatelet agents, adjunctive therapies (hydroxychloroquine, statins and vitamin D), targeted treatment including rituximab, belimumab, and anti-TNF agents, complement inhibition and drugs based on peptides of beta-2-glycoprotein I. In addition, the report summarises potential new players, including coenzyme Q10, adenosine receptor agonists and adenosine potentiation. In each case, the report provides recommendations for clinicians, based on the current state of the art, and suggests a clinical research agenda. The initiation and development of appropriate clinical studies requires a focus on devising suitable outcome measures, including a disease activity index, an optimal damage index, and a specific quality of life index.

Sign in / Sign up

Export Citation Format

Share Document